赵燕,杨文秀,冯江龙
ZHAO Yan,YANG Wenxiu,FENG Jianglong

• 1:贵州医科大学临床医学院病理学教研室
• 2:贵州省人民医院眼科

摘要(Abstract)：

目的:探讨多发性骨髓瘤癌基因(MUM1)蛋白表达与黑色素瘤(MM)患者临床病理特征的关系。方法:收集60例MM患者的临床病理资料,以同期的肿瘤切缘正常组织60例作为对照组,采用免疫组织化学法检测MUM1蛋白表达。结果:MUM1阳性信号定位于细胞核,表现为细胞核的棕褐色颗粒状信号;MM组患者的MUM1蛋白阳性率明显高于对照组,差异有高度统计学意义(P<0.001);MUM1蛋白阳性组和阴性组之间的肿瘤转移、复发差异有统计学意义(P<0.05或P<0.01),但性别、年龄、吸烟、肿瘤直径、TNM分期、肿瘤分化的差异无统计学意义(P>0.05)。结论:MUM1蛋白阳性表达与MM肿瘤的复发、转移有关,可能是MM不良预后的相关因素。
Objective: To explore the relationship and significance between the expression of MUM1 and the clinicopathological characteristics of melanoma.Methods: The clinical pathological diagnosis information of 60 cases of MM patients was collected while 60 patients with normal tumor margin were selected as control group. MUM1 protein expression of them was detected by immunohistochemistry.Results: MUM1 positive signal was located in the nucleus and manifested as the brown granular signal of the nucleus.The positive rate of MUM1 protein in the MM group was significantly higher than that in the control group,and the difference was highly statistically significant(P<0.001).There were statistically significant differences in tumor metastasis and recurrence between the MUM1 protein-positive group and the negative group(P<0.05 or P<0.01),but no statistically significant differences in gender,age,smoking,tumor diameter,TNM stage and tumor differentiation(P>0.05).Conclusion:MUM1 protein can be used as a diagnostic index of the MM.MUM1 protein positive expression is associated with the recurrence and metastasis of MM tumor,which may be a related factor for the poor prognosis of malignant melanoma.

关键词(KeyWords)： 多发性骨髓瘤;黑色素瘤;免疫组织化学;蛋白;病理特征
multiple myeloma;melanoma;immunohistochemistry;protein;pathologi-cal characteristics

Abstract:

Keywords:

基金项目(Foundation): 贵阳市科技局贵州医科大学联合基金(GY2016-4)

作者(Author): 赵燕,杨文秀,冯江龙
ZHAO Yan,YANG Wenxiu,FENG Jianglong

DOI: 10.19367/j.cnki.1000-2707.2019.09.023

参考文献(References)：

• [1] 谷丽娜,桑梅香,尹丹静,等.贲门腺癌组织黑色素瘤相关抗原-A9和-A11表达临床意义研究[J].中华肿瘤防治杂志,2016,23(13):866-871.
• [2] 张兴艳,马志萍,崔文丽,等.弥漫性大B细胞淋巴瘤中 PRDM 1基因甲基化状态与预后的相关性[J].中华病理学杂志,2016,45(12):831-837.
• [3] 温斯健,倪娜娜,张韩,等.组氨酸三聚体核苷结合蛋白1在黑素瘤组织中的表达及其基因启动子甲基化水平研究[J].中华皮肤科杂志,2016,49(7):478-481.
• [4] VENZA M,VISALLI M,CATAALANO T,et al.DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma[J].Oncology Reports,2016,35(4):2451-2460.
• [5] 徐爱国,徐基祥,熊霞.Wip1、Shh、Gli1蛋白在皮肤恶性黑色素瘤细胞中的表达及临床意义[J].实用医学杂志,2016,32(24):4026-4029.
• [6] 袁志明,林泽旭,陈一峰,等.长链非编码RNA TUSC7对人恶性黑色素瘤A375细胞增殖的影响[J].临床与实验病理学杂志,2017,3(4):408-412.
• [7] POSCH C,MOSLEHI H,SANLORENZO M,et al.Pharmacological inhibitors of c-kit block mutant c-kit mediated migration of melanocytes and melanoma cells in vitro and in vivo[J].Oncotarget,2016,7(29):45916-45925.
• [8] QIU H,LI J,FENG Z,et al.Cd19(+) cd20(-) cd27(hi) il-s10-producing b cells are overrepresented in r-chop-treated dlbcl patients in complete remission [J].Clin Exp Pharmacol Physiol,2016,43(9):795-801.
• [9] 孙妍,张清媛,张明辉,等.外周T细胞淋巴瘤MUM1/IRF4蛋白的表达及其临床意义[J].临床肿瘤学杂志,2012,17(3):215-218.
• [10]MAMANE Y,HEYLBROECK C,GENIN P,et al.Interferon regulatory factors:the next generation[J].Gene,1999,237(1):l- 14.
• [11]INGKANINANDA P,VISESSIRI Y,RUTNIN S.Clinicopathological features and prognostic factors of malignant melanoma:a retrospective analysis of thai patients in ramathibodi hospital[J].Journal of the Medical Association of Thailand Chotmaihet Thangphaet,2015,98(8):820-827.
• [12]THOMAS J M,NEWTON B J,A′HERN R,et al.Excision margins in high-risk malignant melanoma[J].The New England Journal of Medicine,2004,8(8):757-766.
• [13]孙妍,张清媛,张明辉,等.外周T细胞淋巴瘤MUM1/IRF4蛋白的表达及其临床意义[J].临床肿瘤学杂志,2012,17(3):215-218.
• [14]CSCO黑色素瘤专家委员会.中国黑色素瘤诊治指南(2011版)[J].临床肿瘤学杂志,2012,17(2):159-171.
• [15]刘洪芹,邹冰清,王纾宜.程序性死亡分子1及其配体和吲哚胺-2,3-双加氧酶1在鼻腔鼻窦恶性黑色素瘤中的表达及其临床意义[J].中华病理学杂志,2017,46(11):782.
• [16]UCCINI S,Al-JADIRY M F,CIPPITELLI C,et al.Burkitt lymphoma in Iraqi children:a distinctive form of sporadic disease with high incidence of EBV+ cases and more frequent expression of MUM1/IRF4 protein in cases with head and neck presentation[J].Pediatric Blood & Cancer,2018,65(12):395-399.

文章评论(Comment)：